RAC race oncology ltd

1.27%

$1.20

RAC - Charts & Price Action, page-25709

First 25709 Last

Share
Profile

Follow
good1234

2,950 Posts.

523

16/05/25

07:22

Post #: 79065297
Share

Originally posted by Mason14: ↑

Nope. After speaking with upper management of other public vehicles, a blackout of significant duration like this can only mean a couple things. When I put this into the context of RAC today and what is needed to sell the RAC of tomorrow, there are some things that come to my mind and they are all exciting.

RAC need a lot of clinical data to deliver the largest possible return for shareholders. With the patent for RC220 already published, the clock is ticking. The CPACS clinical program is now underway, meaning there’s a limited window to build a compelling dataset - one that will likely need to be in place by the (near) completion of a large Phase 2 trial. The last time RAC shareholders received anything preclinical data related was June last year - that is a hell of a lot of time in between drinks.

We need to keep in mind that I have my tin foil hat on and that it is impossible for me to truly know what is happening. I'm probably very wrong. However, as a result of the points above, I believe that there are only a handful of potential scenarios that can play out, which include:

1. Licensing or partnership to expedite the clinical programs of Bisantrene. Even a small geographical deal to somewhere like Japan has huge upside for RAC shareholders at relatively low cost. Such an event validates Bisantrene clinically and commercially in the eyes of a pharmaceutical company and, of course, investors. I imagine such an agreement might include expanding the clinical program for Bisantrene. For example, following the completion of the P1a and establishing the MTCD, a P1b/P2 expansion to the current CPACS trial in the jurisdiction expands the clinical use of Bisantrene into real drug combinations and additional patients beyond breast. Continuing on the Japan as the example, a dedicated P1b/P2 in this jurisdiction builds human data specific to an Asian demographic, which can later be used as evidence in a larger commercial deal.

Something like this addresses RACs need for timely clinical data by utilizing the resources of a larger organisation while also validating Bisantrene clinically and commercially without destroying future potential value.

2. Strategic clinical update to address the targeted therapy synergy program or anti-cancer specific area. The last year has felt like a barren wasteland with regards to updates on stated preclinical programs. It goes without saying that targeted therapy and immunotherapy are enormous areas with a lot of competitors (competitors who would like an advantage). Bisantrene is unique in its mechanisms to kill cancer - death by a thousand cuts comes to mind - while preventing long term toxicity. If these mechanisms have been completely understood and an area by which Bisantrene could explore and unlock huge commercial upside has been researched and revealed, then this could put a buying block on RAC.

Once again, this type of scenario aligns with RACs need for timely clinical data and explains the time required to receive information and determine the best place to direct resources. This could of course happen with funding from an external party.

As an additional point, I do not believe the MOA paper or AML investigator explain the blackout.

If you're after a simple answer, it's about expanding clinical data in the most time-efficient and clinically translatable way possible.

Expand

Also, what’s your view on the future of RAC with respect to multiple uses for Bisantrene?

How can we maximize value over multiple uses, such as cardioprotection now, plus potential FTO, or are we just a cardioprotection drug now - which will probably be large anyway if successful?

Multiple indications will be tricky regarding pricing in my view.

The pot is large though any way you cut it.

I respect your views by the way, and appreciate you sharing the vast amount of work you’ve put into this.

Last edited by good1234: 16/05/25

RAC Price at posting: $1.42 Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

Most investors will get this earnings season wrong. Will you?

ASE

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

First 25709 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.20		Change 0.015(1.27%)		Mkt cap ! $208.4M

Open	High	Low	Value	Volume
$1.20	$1.20	$1.17	$139.7K	118.3K

Buyers (Bids)

No.	Vol.	Price($)
1	666	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.20	7691	3

View Market Depth

No.	Vol.	Price($)
1	1538	1.180
3	22097	1.170
2	10853	1.160
3	30900	1.150
7	13634	1.140

Price($)	Vol.	No.
1.200	7691	3
1.210	9169	2
1.220	2000	1
1.225	4043	2
1.230	2100	1

Last trade - 16.10pm 25/07/2025 (20 minute delay)

RAC (ASX) Chart

RAC - Charts & Price Action, page-25709

Most investors will get this earnings season wrong. Will you?

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

RAC - Charts & Price Action, page-25709

Top Stories

Most investors will get this earnings season wrong. Will you?

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News